Dronabinol/cannabidiol - GW Pharmaceuticals

Drug Profile

Dronabinol/cannabidiol - GW Pharmaceuticals

Alternative Names: GWP-42002/GWP-42003; GWP-42002:GWP-42003; GWP-42003/GWP-42002; GWP-42003:GWP-42002

Latest Information Update: 13 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GW Pharmaceuticals
  • Class Cannabinoids
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioblastoma
  • Preclinical Glioma

Most Recent Events

  • 07 Dec 2015 Dronabinol/cannabidiol - GW Pharmaceuticals receives Orphan Drug status for Glioma in USA prior to December 2015
  • 01 May 2014 Preclinical trials in Glioma in United Kingdom (unspecified route)
  • 31 Oct 2013 Phase-I/II clinical trials in Glioblastoma in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top